BC Week In Review | Sep 13, 2010
Company News

Phenomix endocrine news

Phenomix said it has cut most of its 45 employees and is winding down operations after failing to find a new partner in North America to develop and commercialize diabetes candidate dutogliptin . In April, Forest...
BC Week In Review | Apr 26, 2010
Clinical News

Dutogliptin: Phase III data

Top-line data from the double-blind, international Phase III PROT301 trial in 542 patients showed that both doses of once-daily dutogliptin met the primary endpoint of significantly reducing HbA1c from baseline to week 24 vs. placebo....
BC Week In Review | Apr 26, 2010
Company News

Phenomix, Forest Laboratories deal

Forest ended a 2008 deal with Phenomix granting Forest North American rights to co-develop and commercialize dutogliptin. Forest cited undisclosed "business reasons" for the termination. Further terms were not disclosed. Phenomix intends to seek new...
BC Extra | Apr 21, 2010
Top Story

Phenomix meets endpoint, loses partner

Forest Laboratories Inc. (NYSE:FRX) ended a deal with Phenomix Corp. (San Diego, Calif.) for dutogliptin despite new data showing the compound met the primary endpoint in the Phase III PROT301 trial to treat Type II...
BioCentury | Apr 5, 2010
Finance

2Q Financial Markets Preview: Wanted Dry Powder

Biotech run-ups have historically cooled after 25-30% gains. Thus the question going into the second quarter is whether there's momentum to keep going, or whether the sector will take a breather. The historical numbers are...
BC Week In Review | Dec 7, 2009
Company News

Chiesi, Phenomix deal

Phenomix granted Chiesi exclusive rights to develop and commercialize dutogliptin (PHX1149) in Europe, Brazil, the Commonwealth of Independent States, Turkey and Northern Africa. The dipeptidyl peptidase-4 (DPP-4) inhibitor is in Phase III testing to treat...
BC Extra | Dec 3, 2009
Company News

Phenomix, Chiesi in dutogliptin deal

Phenomix Corp . (San Diego, Calif.) granted Chiesi Farmaceutici S.p.A. (Parma, Italy) exclusive rights to develop and commercialize dutogliptin ( PHX1149 ) in Europe, Brazil, the Commonwealth of Independent States, Turkey and Northern Africa. The dipeptidyl peptidase-4 (DPP-4)...
BioCentury | Jul 6, 2009
Finance

3rd Quarter Stock Preview: Searching for an Even Keel

Rotation out of defensive sectors and the anticipation of U.S. healthcare reform are taking the wind out of the sails of big cap biotech, a trend that's expected to continue through the third quarter. But...
BC Week In Review | Oct 27, 2008
Company News

Phenomix, Forest Laboratories deal

The partners will co-develop and commercialize Phenomix's dutogliptin (formerly PHX1149) to treat Type II diabetes in North America. The dipeptidyl peptidase-4 (DPP-4) inhibitor is in Phase III testing for the indication. The companies will share...
BioCentury | Oct 27, 2008
Finance

Ebb & Flow

Drug delivery and infectious disease company Nektar (NASDAQ:NKTR) expects to end the year with about $440 million in cash, courtesy of the sale of part of its pulmonary delivery business to Novartis (NYSE:NVS; SWX:NOVN) for...
Items per page:
1 - 10 of 28